OTX 101

Drug Profile

OTX 101

Alternative Names: OTX-101; Seciera

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Ocular Technologies
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Keratoconjunctivitis sicca

Most Recent Events

  • 04 Jan 2017 Positive topline efficacy and safety data from the phase III Emerald trial in Keratoconjunctivitis sicca released by Sun Pharma
  • 01 Dec 2016 Ocular Technologies completes the phase III Emerald trial in Keratoconjunctivitis sicca in USA (NCT02688556)
  • 03 Mar 2016 Ocular Technologies announces intention to submit NDA to the US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top